ATE302199T1 - Quinalozinon-derivate - Google Patents

Quinalozinon-derivate

Info

Publication number
ATE302199T1
ATE302199T1 AT99970659T AT99970659T ATE302199T1 AT E302199 T1 ATE302199 T1 AT E302199T1 AT 99970659 T AT99970659 T AT 99970659T AT 99970659 T AT99970659 T AT 99970659T AT E302199 T1 ATE302199 T1 AT E302199T1
Authority
AT
Austria
Prior art keywords
hydrogen atom
alkyl group
äwherein
chem
group
Prior art date
Application number
AT99970659T
Other languages
English (en)
Inventor
Masami Muraoka
Kazuki Matsui
Koji Morishita
Naohito Ohashi
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE302199T1 publication Critical patent/ATE302199T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT99970659T 1998-10-16 1999-10-07 Quinalozinon-derivate ATE302199T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29505098 1998-10-16
PCT/JP1999/005560 WO2000023436A1 (fr) 1998-10-16 1999-10-07 Derives de quinazolinone

Publications (1)

Publication Number Publication Date
ATE302199T1 true ATE302199T1 (de) 2005-09-15

Family

ID=17815680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970659T ATE302199T1 (de) 1998-10-16 1999-10-07 Quinalozinon-derivate

Country Status (10)

Country Link
US (1) US6645971B1 (de)
EP (1) EP1122253B1 (de)
JP (1) JP4484368B2 (de)
KR (1) KR100607634B1 (de)
AT (1) ATE302199T1 (de)
CA (1) CA2347506C (de)
DE (1) DE69926776T2 (de)
ES (1) ES2244243T3 (de)
PT (1) PT1122253E (de)
WO (1) WO2000023436A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100824506B1 (ko) * 2001-08-09 2008-04-22 다이닛본 스미토모 세이야꾸 가부시끼가이샤 퀴나졸리논 유도체
EP1699450A4 (de) * 2003-12-23 2009-11-11 Darpharma Inc Gleichzeitige verabreichung von dopamin-rezeptor-bindungsverbindungen
JP4667789B2 (ja) * 2004-08-23 2011-04-13 大日本住友製薬株式会社 キナゾリノン化合物の酸付加塩の製造方法
JP4643948B2 (ja) * 2004-08-23 2011-03-02 大日本住友製薬株式会社 キナゾリノン化合物の安定化方法
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
ES2393694T3 (es) * 2008-11-20 2012-12-27 Merck Sharp & Dohme Corp. Moduladores alostéricos positivos del receptor de aril metil benzoquinazolinona M1
US8664387B2 (en) 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
WO2011084371A1 (en) * 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
EP3740477A1 (de) 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd C5a-rezeptormodulatoren
EP3740476A1 (de) 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd C5a-rezeptormodulatoren

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4822716B1 (de) * 1968-07-01 1973-07-07
US3819627A (en) * 1968-07-01 1974-06-25 Sandoz Ag 1-substituted-3,4-dihydro-2(1h)-quinazolinones
FR2027023A1 (en) 1968-12-24 1970-09-25 Farmaceutici Italia Substd quinazoline derivs prepn cns depress - ants
US3547921A (en) 1968-12-26 1970-12-15 Sandoz Ag Preparation of 1-substituted-4-aryl-3,4-dihydro-2(1h)-quinazolinones
US3829420A (en) 1970-07-13 1974-08-13 Sumitomo Chemical Co 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
JPS4834598B1 (de) 1970-12-23 1973-10-22
DE2162327C3 (de) * 1970-12-23 1975-09-18 Sumitomo Chemical Co., Ltd., Osaka (Japan) Verfahren zur Herstellung von 3,4-Oihydro-2(1 H)-chinazolinonen
US4099002A (en) 1970-12-23 1978-07-04 Sumitomo Chemical Company, Limited Quinazolinone derivatives and a process for production thereof
BE795519A (fr) * 1972-02-18 1973-06-18 Sumitomo Chemical Co Procede de preparation d'un agent uricosurique
US3812257A (en) * 1972-04-07 1974-05-21 Sumitomo Chemical Co Uricosuric agent
JPS4925270B1 (de) * 1973-04-09 1974-06-28
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS56113769A (en) 1980-02-13 1981-09-07 Sumitomo Chem Co Ltd Novel 2 1h -quinazolinone derivative and its preparation
JPS5795966A (en) 1980-12-04 1982-06-15 Sumitomo Chem Co Ltd Novel 2(1h)-quinazolinone derivative
JP3859738B2 (ja) 1993-05-26 2006-12-20 大日本住友製薬株式会社 キナゾリノン誘導体
ATE174908T1 (de) 1993-05-26 1999-01-15 Sumitomo Pharma Chinazolinonderivate

Also Published As

Publication number Publication date
CA2347506C (en) 2009-06-23
EP1122253B1 (de) 2005-08-17
KR100607634B1 (ko) 2006-08-02
US6645971B1 (en) 2003-11-11
PT1122253E (pt) 2005-11-30
DE69926776T2 (de) 2006-06-08
CA2347506A1 (en) 2000-04-27
DE69926776D1 (de) 2005-09-22
WO2000023436A1 (fr) 2000-04-27
EP1122253A1 (de) 2001-08-08
KR20010080159A (ko) 2001-08-22
ES2244243T3 (es) 2005-12-01
EP1122253A4 (de) 2003-05-28
JP4484368B2 (ja) 2010-06-16

Similar Documents

Publication Publication Date Title
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
ID17851A (id) Persenyawaan heterosiklis, produksi dan pemakaiannya
BR0002936A (pt) Compostos de biciclicarbonil-indol como agentes antiinflamatórios/analgésicos
ATE339409T1 (de) Trizyklische verbindungen
DK0625977T3 (da) Piperazinderivater som 5-1A-antagonister
FI972460A0 (fi) Aniliinijohdannaiset joilla on typpimonoksidisyntaasiesto aktiivisuus
DK1113011T3 (da) Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer
ATE302199T1 (de) Quinalozinon-derivate
DE69505470D1 (de) Pyrrolocarbazol
DE69617226T2 (de) Piperidinderivate.
IL136510A (en) Acylated hetero-alicyclic derivatives and pharmaceutical compositions containing the same
EP1197211A4 (de) Wirkstoffe zur vorbeugung und behandlung von krebs
EP1340753A4 (de) Carbamatderivate, verfahren zu deren herstellung und deren verwendung
DE60103732D1 (de) Pyrimidinderivate mit antitumor-wirkung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1122253

Country of ref document: EP